Treace Medical Concepts Inc TMCI shares are trading lower after the company reported worse-than-expected third-quarter financial results and lowered full-year 2023 revenue guidance below estimates.
What To Know: Treace Medical Concepts reported earnings losses of 28 cents per share which missed the analyst consensus estimate of losses of 26 cents, a 27.27% decrease over losses of 22 cents per share from the same period last year.
The company reported quarterly sales of $40.76 million which missed the analyst consensus estimate of $42.05 million, a 23.30% increase over sales of $33.05 million in the same period last year.
Cash, cash equivalents, marketable securities and investments receivable totaled $128.2 million as of Sept. 30.
The company lowered full-year revenue guidance from between $191 million and $197 million to between $182 million and $186 million, versus the $194.32 million estimate.
"We're pleased to report substantial gains in our key performance metrics during the third quarter, including 36% year-to-date revenue growth and a significant increase in our surgeon base, which now totals 2,691, a 21% increase over the prior year," said John T. Treace, CEO, founder and board member of Treace Medical Concepts.
"We also achieved a record blended average selling price of $6,311, driven by the early impact of our new technologies, and we are particularly excited about the opportunity for our SpeedPlate fixation platform."
Related Link: Lightspeed Faction Ignites Blockchain Revolution With $285M Venture Fund
TMCI Price Action: Shares of TMCI were down 16.50% at $8.35 in the after-hours session at the time of publication Thursday, according to Benzinga Pro.
Photo: Darko Stojanovic from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
